TP53 and neuroblastoma: However, treatment with JQ1 resulted in more resistant NB cell lines to NK cell-activating receptors, which—along with the inhibition of MYCN—impaired also the function of c-MYC and p53 that regulate the expression of specific ligands (ULBP1-3) for NKG2D-activating receptor [165].